A Phase Ib, Single-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Injections of M6495 (Anti-ADAMTS-5 Nanobody) in Participants With Symptomatic Knee Osteoarthritis
Phase of Trial: Phase I
Latest Information Update: 24 Jan 2019
At a glance
- Drugs M 6495 (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors Merck KGaA
- 10 Oct 2018 Planned End Date changed from 22 Apr 2019 to 22 May 2019.
- 10 Oct 2018 Planned primary completion date changed from 22 Apr 2019 to 22 May 2019.
- 10 Oct 2018 Status changed from not yet recruiting to recruiting.